【摘要】 目的探讨奥扎格雷钠对慢性肺源性心脏病 (CPHD)急性加重期的疗效。方法将 72例CPHD急性加重期随机分成治疗组和对照组 ,另设一健康组。两组均给予常规抗感染、祛痰、解痉、低流量吸氧等治疗。治疗组加用奥扎格雷钠 80mg溶于0 9%氯化钠溶液 2 5 0ml中 ,每日 1次静脉滴注 ,10天为 1个疗程。于治疗前后同步检测患者血浆血栓素B2 (TXB2 )、6 酮 前列腺素 ( 6 keto PGF1α)、D 二聚体 (D dimer)及血气分析 ,同时观察症状和体征变化 ,并与健康组进行比较。结果治疗前两组TXB2 、D dimer和PaCO2 显著高于健康组 (P <0 0 1) ,6 keto PGF1α、PaO2 显著低于健康组 (P <0 0 1) ;治疗后 ,治疗组TXB2 、D dimer和PaCO2 显著降低 (P <0 0 1) ,6 keto PGF1α、PaO2 显著升高 (P <0 0 1) ,症状和体征显著改善 (P <0 0 5 ) ;对照组TXB2 、6 keto PGF1α、D dimer、PaO2 和PaCO2 均无显著性变化 (P >0 0 5 )。结论奥扎格雷钠对CPHD急性加重期治疗有效更多还原

【Abstract】 Objective To investigate the efficacy of Sodium Ozagrel in treatment of chronic pulmonary heart disease (CPHD) at acute attack phase. Methods 72 patients with CPHD in acute attack phase were randomly divided into study group (36 cases) and control group (36 cases).All of the patients in two groups were given the same routine treatments,like anti-infection,expectorant,spasmolysis and low flow oxygen inhalation.In study group,besides these routine treatments,80 mg Sodium Ozagrel in 250 ml 0.9% Sodium chloride solution was given intravenously once a day.The course of treatment lasted 10 days.The concentrations of plasma thromboxane B 2 (TXB 2 ),6-keto-PGF 1α,D-dimer,blood PaO 2 and PaCO 2 were detected for the two groups before and after the treatment.Meanwhile, the patients’s ymptoms and signs were observed.The parameters in the two groups were compared with those from 20 healthy human subjects. Results The concentrations of plasma TXB 2,D-dimer and blood PaCO 2 were significantly increased (P<0.01),while the levels of plasma 6-keto-PGF 1α,blood PaO 2 were significantly decreased (P<0.01)before the treatment in the two study group when compared with those in healthy subjects.After the treatment,in study group,the levels of plasma TXB 2,D-dimer and blood PaCO 2 were significantly decreased(P<0.01),whereas the concentrations of plasma 6-keto-PGF 1α and blood PaO 2 were significantly increased (P<0.01).The symptoms and signs were markedly improved compared with those in control group(P<0.05);the concentrations of plasma TXB 2,6-keto-PGF 1α ,D-dimer,blood PaO 2 and PaCO 2 showed no significant difference in the control group(P>0.05). Conclusions Sodium Ozagrel was found effective to patients with CPHD in acute attack phase.更多还原